BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

Source: Nasdaq GlobeNewswire / 03 Nov 2023 12:03:00   America/New_York